Education > XRAY > Search Results

FORCE's eXaming the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

1 through 10 of 11

Relevance: High

pointerRelevance

Strength of Science: High

pointerStrength of Science
View Related Clinical Trials

Update : FDA approves the PARP inhibitor olaparib (Lynparza) in combination with bevacizumab (Avastin) as maintenance therapy for some women with advanced ovarian cancer

Most relevant for: Women with advanced ovarian cancer whose tumor has a BRCA mutation or a type of tumor marker called homologous recombination deficiency (HRD)

The FDA has approved the first drug combination to be used as a first-line maintenance therapy for some women with advanced ovarian cancer. (7/7/2020)

Read More
FDA approves the PARP inhibitor olaparib (Lynparza) in combination with bevacizumab (Avastin) as maintenance therapy for some women with advanced ovarian cancer

Relevance: Medium-High

pointerRelevance

Strength of Science: Medium-High

pointerStrength of Science

Research Timeline: Human Research

pointerResearch Timeline
View Related Clinical Trials

Study : Promising research using a PARP inhibitor to treat metastatic breast cancer in people with an inherited PALB2 mutation or a tumor mutation in BRCA1 or BRCA2

Most relevant for: People with metastatic breast cancer with an inherited mutation or tumor with a BRCA mutation

Early results of a small study showed that women with metastatic breast cancer and an inherited  mutation in PALB2 or an acquired tumor mutation in BRCA1 or BRCA2 benefitted from the PARP inhibitor olaparib (Lynparza). (6/18/20)

Read More
Promising research using a PARP inhibitor to treat metastatic breast cancer in people with an inherited PALB2 mutation or a tumor mutation in BRCA1 or BRCA2

Relevance: High

pointerRelevance

Research Timeline: Post Approval

pointerResearch Timeline
View Related Clinical Trials

Update : PARP inhibitors, rucaparib (Rubraca) and olaparib (Lynparza) receive FDA approval for metastatic prostate cancer

Most relevant for: Men with metastatic castration-resistant prostate cancer who have certain inherited or tumor mutations in DNA repair genes

The FDA approved two PARP inhibitors, rucaparib (Rubraca) and olaparib (Lynparza) for treatment of metastatic castration-resistant prostate cancer (mCRPC) in men who have certain inherited mutations or tumor mutations. (6/1/20)

Read More
PARP inhibitors, rucaparib (Rubraca) and olaparib (Lynparza) receive FDA approval for metastatic prostate cancer

Relevance: Medium-High

pointerRelevance

Strength of Science: Medium-High

pointerStrength of Science

Research Timeline: Human Research

pointerResearch Timeline
View Related Clinical Trials

Study : Research on the PARP inhibitor talazoparib (Talzenna) for early-stage breast cancer is promising

Most relevant for: People with early stage breast cancer who have an inherited BRCA mutation

The PARP inhibitor talazoparib (Talzenna) has been useful for treatment of advanced or metastatic breast cancer for patients with BRCA mutations. A preliminary study showed that the majority of patients who took talazoparib alone before surgery for early-stage breast cancer had effective treatment and manageable side effects. Expanded clinical trials are in progress to verify this result. (10/4/19)

Read More
Research on the PARP inhibitor talazoparib (Talzenna) for early-stage breast cancer is promising

Relevance: Medium-High

pointerRelevance

Strength of Science: Medium

pointerStrength of Science

Research Timeline: Post Approval

pointerResearch Timeline
View Related Clinical Trials

Study : Inherited mutations in metastatic breast cancer patients

Most relevant for: People with metastatic breast cancer

Recent research shows that a significant portion of patients with metastatic breast cancer have harmful mutations in a gene associated with hereditary breast cancer and increased breast cancer risk. (9/26/19)

Read More
Inherited mutations in metastatic breast cancer patients

Relevance: High

pointerRelevance

Strength of Science: High

pointerStrength of Science

Research Timeline: Human Research

pointerResearch Timeline
View Related Clinical Trials

Study : Results from the POLO trial: Olaparib may delay cancer progression in metastatic pancreatic cancer patients with BRCA mutations.

Most relevant for: People diagnosed with pancreatic cancer who have a BRCA mutation

Note: On 12/27/19, the FDA approved olaparib for treatment of pancreatic cancer in people with a BRCA mutation based on the results of the POLO study.

The POLO clinical trial looks at whether the PARP inhibitor olaparib improves outcomes for those with metastatic pancreatic cancer after platinum-based chemotherapy.  (7/3/19) 

Read More
Results from the POLO trial: Olaparib may delay cancer progression in metastatic pancreatic cancer patients with BRCA mutations.

Relevance: Medium-High

pointerRelevance

Research Timeline: Post Approval

pointerResearch Timeline

Guideline : Breast surgeons recommend genetic testing for all breast cancer patients

Most relevant for: Anyone diagnosed with breast cancer

Summary: 

The American Society of Breast Surgeons published statement on genetic testing for hereditary breast cancer on February 10, 2019. It includes recommendations about who should be tested. Among these is the recommendation that all breast cancer patients get genetic testing, as well as women who do not have breast cancer but fit the National Comprehensive Cancer Network (NCCN) guidelines. (3/25/19)

Read More
Breast surgeons recommend genetic testing for all breast cancer patients

Relevance: High

pointerRelevance

Quality of Writing: High

pointerQuality of Writing

Article : The cost of cancer care and impact of financial hardship on treatment

Most relevant for: Anyone diagnosed with cancer

Summary:

Several recent studies on the cost of cancer care show the negative effects on cancer patients. In this XRAYS we review a recent article by Kaiser Health News and associated studies about the financial impact of breast cancer treatment and cost of precision medicine. (2/8/19)

Read More
The cost of cancer care and impact of financial hardship on treatment

Relevance: Medium-High

pointerRelevance

Strength of Science: High

pointerStrength of Science

Study : BRCA testing in young women with breast cancer

Most relevant for: Young women diagnosed with breast cancer who have not yet had genetic testing

National guidelines recommend genetic testing for BRCA mutations in young women who are diagnosed with breast cancer. However, little is known about how women decide to get testing, or how they use genetic information to decide on treatment options. This study found that genetic testing is increasing among young breast cancer survivors, and it explores some of the factors that play into patients’ decision making about genetic testing. (3/22/16)

Read More
BRCA testing in young women with breast cancer

Relevance: Medium

pointerRelevance

Strength of Science: Medium

pointerStrength of Science

Research Timeline: Human Research

pointerResearch Timeline

Most relevant for: Breast cancer patients who have an inherited mutation and breast cancer patients who developed leukemia after treatment for breast cancer.

The population of breast cancer survivors in the United States is increasing. One rare but dangerous long-term effect of breast cancer treatment is an increased risk of leukemia, a type of bone marrow cancer. A recent study uncovered a potential genetic basis for this condition. (01/26/2015)

Read More
Potential genetic basis for breast cancer survivors who develop therapy-related leukemia